))
DME/Retina Edition: Top Headlines for Week of August 5, 2024
Manage episode 433131307 series 3560281
Healio에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Healio 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more. Read the full coverage here:
Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD
VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME
DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema
Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema
VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years
References:
Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Phu A, et al. J Diabetes Complications. 2024;doi:10.1016/j.jdiacomp.2024.108808.
Steinle NC. Durability of combination therapy of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ with ranibizumab in nAMD or aflibercept in DME. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
121 에피소드
공유
